Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.

Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research31 Oct 2005Cited by 31 (Europe PMC)

PMID16418784DOI10.1359/jbmr.051020PepBankPUB-16418784

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, adding teriparatide to HRT increased spine BMD more than HRT alone.
In plain wordsAdding teriparatide increased spine bone density more than HRT alone in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine BMD
Study
n = 247
Comparator
HRT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Measurements
Spine BMD increase
14%
teriparatide plus HRT
Spine BMD increase
3%
HRT alone
Source sentences
Summary
Compared with HRT alone, TPTD40 + HRT produced significant (p < 0.001) increases in spine BMD (14% versus 3%), total hip (5.2% versus 1.6%), and femoral neck (5.2% versus 2%) at study endpoint.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878401
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, adding teriparatide to HRT increased total hip BMD more than HRT alone.
In plain wordsAdding teriparatide increased hip bone density more than HRT alone in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD
Study
n = 247
Comparator
HRT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Measurements
Total hip BMD increase
5.2%
teriparatide plus HRT
Total hip BMD increase
1.6%
HRT alone
Source sentences
Summary
Compared with HRT alone, TPTD40 + HRT produced significant (p < 0.001) increases in spine BMD (14% versus 3%), total hip (5.2% versus 1.6%), and femoral neck (5.2% versus 2%) at study endpoint.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878402
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, adding teriparatide to HRT increased femoral neck BMD more than HRT alone.
In plain wordsAdding teriparatide increased femoral neck bone density more than HRT alone in postmenopausal women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD
Study
n = 247
Comparator
HRT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Measurements
Femoral neck BMD increase
5.2%
teriparatide plus HRT
Femoral neck BMD increase
2%
HRT alone
Source sentences
Summary
Compared with HRT alone, TPTD40 + HRT produced significant (p < 0.001) increases in spine BMD (14% versus 3%), total hip (5.2% versus 1.6%), and femoral neck (5.2% versus 2%) at study endpoint.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878403
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, whole body BMD was higher with teriparatide plus HRT, but not in the HRT group.
In plain wordsWhole body bone density was higher with teriparatide plus HRT but not in the HRT group.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseWhole body BMD
Study
n = 247
Comparator
HRT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Source sentences
Summary
BMD, in whole body and ultradistal radius, was higher, and in the one-third distal radius was lower, in the combination therapy but not in the HRT group.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878404
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, ultradistal radius BMD was higher with teriparatide plus HRT, but not in the HRT group.
In plain wordsUltradistal radius bone density was higher with teriparatide plus HRT but not in the HRT group.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUltradistal radius BMD
Study
n = 247
Comparator
HRT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Source sentences
Summary
BMD, in whole body and ultradistal radius, was higher, and in the one-third distal radius was lower, in the combination therapy but not in the HRT group.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878405
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, one-third distal radius BMD was lower with teriparatide plus HRT, but not in the HRT group.
In plain wordsOne-third distal radius bone density was lower with teriparatide plus HRT but not in the HRT group.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseOne-third distal radius BMD
Study
n = 247
Comparator
HRT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Source sentences
Summary
BMD, in whole body and ultradistal radius, was higher, and in the one-third distal radius was lower, in the combination therapy but not in the HRT group.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878406
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, adding teriparatide to HRT increased serum bone-specific alkaline phosphatase versus HRT alone.
In plain wordsAdding teriparatide increased blood bone-specific alkaline phosphatase compared with HRT alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone-specific alkaline phosphatase
Study
n = 247
Comparator
HRT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Source sentences
Summary
Serum bone-specific alkaline phosphatase and urinary N-telopeptide/Cr were increased significantly (p < 0.01) in the women receiving TPTD40 + HRT compared with HRT.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878407
08HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, adding teriparatide to HRT increased urinary N-telopeptide/Cr versus HRT alone.
In plain wordsAdding teriparatide increased the urinary bone resorption marker compared with HRT alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUrinary N-telopeptide to creatinine
Study
n = 247
Comparator
HRT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Source sentences
Summary
Serum bone-specific alkaline phosphatase and urinary N-telopeptide/Cr were increased significantly (p < 0.01) in the women receiving TPTD40 + HRT compared with HRT.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878408
09HumanRandomized controlled trialSafety outcome
In postmenopausal women, adding teriparatide to HRT increased reported nausea versus HRT alone.
In plain wordsAdding teriparatide caused more reported nausea than HRT alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNausea
Study
n = 247
Comparator
HRT alone
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Source sentences
Summary
Nausea and leg cramps were more frequently reported in the TPTD40 + HRT group.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878411
10HumanRandomized controlled trialSafety outcome
In postmenopausal women, adding teriparatide to HRT increased reported leg cramps versus HRT alone.
In plain wordsAdding teriparatide caused more reported leg cramps than HRT alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLeg cramps
Study
n = 247
Comparator
HRT alone
Outcome group
Adverse events · Musculoskeletal
Studied dose
40 microg/day · subcutaneous · Median 13.8 monthsAs given in this study (human).
Source sentences
Summary
Nausea and leg cramps were more frequently reported in the TPTD40 + HRT group.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
Report a problemFND-1641878412

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome
Postmenopausal women tolerated both teriparatide plus HRT and HRT alone well.
In plain wordsWomen tolerated teriparatide plus HRT and HRT alone well.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTreatment tolerability
Study
n = 247
Comparator
HRT alone
Outcome group
Adverse events · Whole body
Source sentences
Summary
Patients tolerated both the treatments well.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1641878410
12HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
The BMD and bone marker profile with added teriparatide was similar across prior HRT treatment subgroups.
In plain wordsBone density and bone marker patterns with added teriparatide were similar across prior HRT treatment subgroups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBMD and bone marker profile by prior HRT
Study
n: not reported in source
Comparator
HRT-pretreated versus non-pretreated subgroups
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
A similar profile of BMD and bone markers was evident in both randomized patients as well as in subgroups of patients not pretreated or pretreated with HRT.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled study was conducted in postmenopausal women with either low bone mass or osteoporosis.
Summary · context
Patients were randomized to placebo subcutaneous plus HRT (n = 125) or teriparatide 40 microg/day (SC) plus HRT (TPTD40 + HRT; n = 122) for a median treatment exposure of 13.8 months.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1641878409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.